20615-76-3

Basic information

• Product Name: Benzenemethanol, 2-azido-
• CAS NO: 20615-76-3
• Molecular Formula: C7H7N3O
• Molecular Weight: 149.152
• Mol File: 20615-76-3.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 2-azido-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 2-azido-(20615-76-3)
• EPA Substance Registry System: Benzenemethanol, 2-azido-(20615-76-3)

Safety Data

• Hazardous Substances Data: 20615-76-3(Hazardous Substances Data)

Usage

General Description

Benzenemethanol, 2-azido- is a chemical compound with the molecular formula C7H7N3O. It is a derivative of benzyl alcohol, with an azide group attached to the carbon atom. Benzenemethanol, 2-azido- is known for its reactivity in azide-alkyne click chemistry, which is commonly used for bioconjugation and materials synthesis. It is often used as a precursor in the synthesis of various organic compounds and pharmaceuticals. However, it is important to handle this compound with caution, as the azide group can be explosive and toxic if mishandled. Therefore, proper safety protocols should be followed when working with benzenemethanol, 2-azido-.

Upstream product

• 5344-90-1 2-Aminobenzyl alcohol 
• 31656-92-5 1-azido-2-methyl-benzene 
• 16714-25-3 2-azidobenzaldehyde 
• 552-89-6 2-nitro-benzaldehyde 
• 612-25-9 2-Nitrobenzyl alcohol 
• 87199-14-2 2-(hydroxymethyl)phenylboronic acid 
• 45754-05-0 o-Hydroxymethyl-benzoldiazonium 
• 118-92-3 anthranilic acid 

Downstream Products

• 159428-13-4 Bis(2,2'-diazidobenzyl) ether 
• 120692-81-1 1-azido-2-(chloromethyl)benzene 
• 940938-72-7 C₁₀H₁₀ClN₃O 
• 1134435-41-8 O-(2-azidobenzyl)-N-(4-chlorophenyl)thiocarbamate 
• 271-58-9 anthranil 
• 1443134-51-7 3-{1N-(2-hydroxymethyl phenyl)-1H-1,2,3-triazol-4yl}methyloxy betulinic acid 
• 1472652-05-3 [2-(5-iodo-4-phenyl-1H-1,2,3-triazol-1-yl)phenyl]methanol 
• 1237588-36-1 2-(4-phenyl-1H-1,2,3-triazol-1-yl)phenylmethanol 
• 127766-67-0 Acetic acid (4S,5R,6S)-6-(2-phenyl-[1,3]dithiolan-2-ylmethyl)-4-phenylsulfanyl-1-(2,2,2-trifluoro-acetyl)-1,2,3,4,5,6-hexahydro-benzo[b]azocin-5-yl ester 
• 133035-18-4 Acetic acid (4S,5R,6S)-4-benzenesulfinyl-6-(2-oxo-2-phenyl-ethyl)-1-(2,2,2-trifluoro-acetyl)-1,2,3,4,5,6-hexahydro-benzo[b]azocin-5-yl ester 
• 127766-68-1 Acetic acid (4S,5R,6S)-6-(2-oxo-2-phenyl-ethyl)-4-phenylsulfanyl-1-(2,2,2-trifluoro-acetyl)-1,2,3,4,5,6-hexahydro-benzo[b]azocin-5-yl ester 
• 127766-65-8 (4R,5S)-5-[(R)-1-(2-Amino-phenyl)-2-(2-phenyl-[1,3]dithiolan-2-yl)-ethyl]-4-phenylsulfanyl-dihydro-furan-2-one 
• 127766-69-2 Acetic acid (Z)-(5S,6S)-6-(2-oxo-2-phenyl-ethyl)-1-(2,2,2-trifluoro-acetyl)-1,2,5,6-tetrahydro-benzo[b]azocin-5-yl ester 
• 127766-66-9 (4S,5R,6S)-6-(2-Phenyl-[1,3]dithiolan-2-ylmethyl)-4-phenylsulfanyl-1,2,3,4,5,6-hexahydro-benzo[b]azocin-5-ol 

Relevant articles and documents

Synthesis of 2,3,4-tri-substituted 3,4-dihydroquinazolines via tandem nucleophilic addition/epoxy ring-opening cyclization methodology using N-(2-Oxiranylphenyl)carbodiimides with nucleophiles

N-(2-Oxiranylphenyl)carbodiimides, which were synthesized via an aza-Wittig reaction of the corresponding functionalized iminophosphoranes with aromatic and aliphatic isocyanates, underwent O-, S-, C-, or N-nucleophilic addition onto a cumulene, followed by an epoxy ring-opening cyclization with the newly formed NH-nucleophile in a one-pot reaction to furnish 2,3-disubstituted 4-(hydroxymethyl)-3,4-dihydroquinazolines in a highly stereospecific manner. The Japan Institute of Heterocyclic Chemistry.

Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II

Aminopeptidase N (APN) has been proved to be deeply associated with cancer angiogenesis, metastasis and invasion. Therefore, APN gains increasing attention as a promising anti-tumor target. In the current study, we report the design, synthesis, biological evaluation and structure-activity relationship of one new series of leucine ureido derivatives containing the 1,2,3-triazole moiety. Among them, compound 31f was identified as the best APN inhibitor with IC50 value being two orders of magnitude lower than that of the positive control bestatin. Compound 31f possessed selective cytotoxicity to several tumor cell lines over the normal cell line human umbilical vein endothelial cells (HUVECs). Notably, when combined with 5-fluorouracil (5-Fu), 31f exhibited synergistic anti-proliferation effect against several tumor cell lines. At the same concentration, 31f exhibited much better anti-angiogenesis activities than bestatin in the HUVECs capillary tube formation assay and the rat thoracic aorta rings test. In the in vitro anti-invasion assay, 31f also exhibited superior potency over bestatin. Moreover, considerable in vivo antitumor potencies of 31f alone or in combination with 5-Fu were observed without significant toxic signs in a mouse heptoma H22 tumor transplant model.

Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan

Chemical probes of microRNA (miRNA) function are potential tools for understanding miRNA biology that also provide new approaches for discovering therapeutics for miRNA-associated diseases. MicroRNA-21 (miR-21) is an oncogenic miRNA that is overexpressed in most cancers and has been strongly associated with driving chemoresistance in cancers such as renal cell carcinoma (RCC). Using a cell-based luciferase reporter assay to screen small molecules, we identified a novel inhibitor of miR-21 function. Following structure-activity relationship studies, an optimized lead compound demonstrated cytotoxicity in several cancer cell lines. In a chemoresistant-RCC cell line, inhibition of miR-21 via small molecule treatment rescued the expression of tumor-suppressor proteins and sensitized cells to topotecan-induced apoptosis. This resulted in a >10-fold improvement in topotecan activity in cell viability and clonogenic assays. Overall, this work reports a novel small molecule inhibitor for perturbing miR-21 function and demonstrates an approach to enhancing the potency of chemotherapeutics specifically for cancers derived from oncomir addiction.